Lymphoplasmacytic Lymphoma Completed Phase 2 Trials for Imexon (DB05003)

IndicationStatusPhase
DBCOND0031072 (Lymphoplasmacytic Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01314014Imexon for Relapsed Follicular and Aggressive LymphomasTreatment